Day Traders, Penny Stocks, Stock Options, Futures and Forex

A Newsletter that provides real unbiased picks! Worth a try!

h o t t e s t p i c k s . n e t

Note: Copy and Paste the link above into the browser without the spaces to get more information.

Tips from professional stock analysts and there stock report with adequate information. That has made thousands of dollars in profit for its readers.

_____________________________
Get yourself updated on stocks by subscribing to this stock report!

This newsletter is a sure guide to your great success in terms of stock picks.



SUBSCRIBE NOW

mBeach Software Inc. Updates on Progress in Regulatory Qualifications Applications
.
Companies:MBEACH SOFTWARE INC.Related Quotes
Symbol Price Change
MBHS.OB 0.30 0.00


{"s" : "mbhs.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: mBeach Software Inc. On Monday August 30, 2010, 9:00 am EDT

TEL AVIV, Israel, Aug. 30, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today announced its initiation of early stage activities to enter requests for regulatory approvals, required for every Medical Device. The approvals will be for clinical trials and marketing qualifications. The qualifications to be requested at this early stage will include FDA approvals, CE approvals for marketing in the EU, and being recognized by Reimbursement programs.



Completing these regulatory procedures will pave the way for local clinical trials and a full commercial launch of SkinScan 650, SCS's non-invasive, point-of-care system to detect and identify different types of skin cancers. mBeach expects to receive the initial approvals, for clinical trials mainly, by mid 2011. These requested clinical trial approvals, follow the clinical trials conducted by mBeach wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS"), in Israel, with the Ministry of health, Medical Device qualification Department and the international Helsinki approval for conducting clinical trials.



mBeach CEO Yossi Biderman commented, "The early stage regulatory approach, adopted by mBeach, is due to the lengthy regulatory procedures. We expect the approvals to be staggered over a two year period, unless facing unforeseeable obstacles. These requested and required approvals form a basic component in the heath and marketing strategy defined by mBeach. This will help mBeach achieve its two major goals of improving quality of life for millions of people around the world and will greatly increase shareholder value. These approvals combined with a growing market demand and technical innovative approach, will have on the final product what we think will be a boosting impact. We expect our SkinScan 650, a non-invasive, point-of-care, doctors decision supporting device, to provide the Medical practitioner a much needed user friendly diagnostic solution."



About SCS



Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.



Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.



For more information on SCS, visit Skin Cancer Scanning Ltd. (SCS) :: Symbol (OTCBB): MBHS

mBeach Software Inc. Extends Global Patent Protection
.
Companies:MBEACH SOFTWARE INC.Related Quotes
Symbol Price Change
MBHS.OB 0.31 0.00


{"s" : "mbhs.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: mBeach Software Inc. On Tuesday August 31, 2010, 4:00 pm EDT

TEL AVIV, Israel, Aug. 31, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today announced the filing of additional patent applications under the framework of the Patent Cooperation Treaty (PCT). This move will facilitate the company's strategy to enter new international markets for its advanced, non-invasive system to detect and identify skin cancer.



Skin Cancer Scanning Ltd. ("SCS"), the wholly owned subsidiary, has already submitted a patent application in the United States (application number 11/464,838) with a priority date of August 2006. The patent office is currently examining this application and the company expects the patent to be approved and published by the end of 2010.



In addition to the United States, SCS has extended its patent applications in many important markets around the world. These countries include Canada, Japan, Australia, China, South Korea, New Zealand, Israel, South Africa, Brazil, Mexico, Russia and the Commonwealth of Independent States (CIS), Ukraine, and the European Union. These patent applications have now reached the national phase of registration.



These Patent applications are now at the stage of being translated into the relevant national languages of the various countries mentioned.



This is the stage before entering final review by each country's patent examination committees.



"Our intellectual property is one of the company's most valuable assets," said mBeach CEO Yossi Biderman. "We are taking all necessary measures to protect this asset, including patent applications and other appropriate actions. International growth is an important part of our strategy for growth. We want to make sure we have the right patent protection in all our major potential markets as soon as possible."



About SCS



Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.



Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.



For more information on SCS, visit Skin Cancer Scanning Ltd. (SCS) :: Symbol (OTCBB): MBHS.



Forward Looking Statements

A Newsletter that provides real unbiased picks! Worth a try!

pennyalerts.info

Finding High Revenue Growth Penny Stocks? Find no more, subscribe to our newsletter today!

__________________
Subscribe Now!